Literature DB >> 10792564

Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?

A H Miners1, C A Sabin, K H Tolley, C A Lee.   

Abstract

OBJECTIVES: To assess how many hospital visits primary prophylaxis with clotting factor could prevent.
DESIGN: The potential for reducing hospital visits was assessed by comparing rates of in-patient, Out-patient and day-case visits per patient-year for individuals with severe (< 1 IU dL-1) haemophilia who had never received primary prophylaxis with attendance rates for individuals with mild/moderate (1-50 IU dL-1) haemophilia. Hospital attendance data were collected retrospectively for the period 1988-97 inclusive for individuals who were aged 18 years or over.
SETTING: Data were obtained on patients who were registered at the Katharine Dormandy Haemophilia Centre (KDHC), London, UK. OUTCOME MEASURES: In-patient stays, Out-patient and day-case visits.
RESULTS: Individuals with mild/moderate haemophilia were 45% (31-56), 36% (30-41) and 70% (68-73) less likely to have required in-patient, Out-patient and day-case visits than were individuals with severe haemophilia. HIV serostatus and age were also shown to be significant and independent predictors of the rate of Out-patient and day-case visits, but not the rate of in-patient stays.
CONCLUSION: These results suggest that primary prophylaxis for individuals with severe haemophilia could significantly reduce the demand for in-patient stays, and Out-patient and day-case visits.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10792564     DOI: 10.1046/j.1365-2796.2000.00633.x

Source DB:  PubMed          Journal:  J Intern Med        ISSN: 0954-6820            Impact factor:   8.989


  2 in total

1.  Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia.

Authors:  Alexander H Miners; Caroline A Sabin; Keith H Tolley; Christine A Lee
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

Review 2.  Haemophilic factors produced by transgenic livestock: abundance that can enable alternative therapies worldwide.

Authors:  K E Van Cott; P E Monahan; T C Nichols; W H Velander
Journal:  Haemophilia       Date:  2004-10       Impact factor: 4.287

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.